Pharmacotherapy of chronic alcoholism: A review

Drugs of Today

Volumn 35, Issue 1, 1999, Pages 27-33

  Singh, Amarendra N ^a   Srivastava, Shrikant ^b   Jainar, Ashok Kumar ^a  

^a WALSGRAVE HOSPITAL   (United Kingdom)

^b NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ACAMPROSATE; ALCOHOL; DISULFIRAM; LITHIUM; NALTREXONE; NITREFAZOLE; OPIATE ANTAGONIST; SEROTONIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOL CONSUMPTION; ALCOHOLISM; GABAERGIC SYSTEM; PATIENT COMPLIANCE; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0032979739     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.1.522944     Document Type: Review

References (47)

1. Rush, B. An Inquiry Into the Effects of Ardent Spirits Upon the Human Body and Mind, Vol. 6. New York 1811.
2. Singh, A.N. Psychopharmacological management of alcoholism and associated syndromes. Ind Med J 1994, 2: 2-6.
3. Goodwin, D.W., Graze, S.B. Alcoholism. In: Psychiatric Diagnosis, 4th Ed. Oxford University Press: New York 1989, 170-205.
4. Clark, W.D. Alcoholism: Blocks to diagnosis and treatment. Am J Med 1981, 71: 275-85.
5. Schukitt, M.A. Alcohol-related disorders. In: Comprehensive Textbook of Psychiatry, 6th Ed. Kaplan, H.I., Sadock, B.J. (Eds.). Williams & Wilkins: Philadelphia 1995, 775-90.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. American Psychiatric Association: Washington 1994.
7. Imperato, A., Dichiara, G. Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 1986, 239: 219-28.
8. Benjamin, D., Grant, E.R., Poherecky, L.A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993, 621: 137-40.
9. Vescovi, P.P., Coiro, V., Volpi, R. et al. Plasma β-endorphin but not met-enkephalin levels are abnormal in chronic alcoholics. Alcohol 1992, 27: 471-5.
10. Ferriera, L., Soares, D.A., Silva, P. 5-Hydroxytryptamine and alcoholism. Hum Psychopharmacol 1991, 6: 521-4.
11. 3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 1989, 164: 515-9.
12. Gold, M.S. The neurobiology of addictive disorders. In: The Principles and Practice of Addictions in Psychiatry. Miller, N.S. (Ed.). WB Saunders Co.: Philadelphia 1997, 65-9.
13. Hunt, W.A. Neuroscience research: How has it contributed to our understanding of alcohol and alcoholism? A review. Alcohol Clin Exp Res 1993, 17: 1055-65.
14. Fuller, R.K., Branchley, L., Brightwell, D.R. et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986, 256: 1449-55.
15. Fuller, R.F., Roth, H.P. Disulfiram for treatment of alcoholism: An evaluation in 128 men. Ann Intern Med 1979, 90: 901-4.
16. Arana, G.W., Hyman, S.E. Handbook of Psychiatric Drug Therapy, 2nd Ed. Little Brown: Boston 1991.
17. Peachey, J.E., Brien, J.F., Loomis, C.W. A study of calcium carbamide-ethanol interaction in man: Symptom response. Alcohol Clin Exp Res 1980, 4: 332-9.
18. Luthin, G.R., Tabakoff, B. Activation of adenylate cyclase by alcohol requires the nucleotide-binding protein. J Pharmacol Exp Ther 1984, 228: 579-87.
19. Fadda, F., Mosca, E., Colombo, G. et al. Effect of spontaneous ingestion of ethanol on brain dopamine metabolism. Life Sci 1984, 44: 281-7.
20. Lukas, S.E., Mendelson, J.H. Electroencephalographic activity and plasma ACTH during ethanol-induced euphoria. Biol Psychiatry 1988,23: 141-8.
21. Volpicelli, J.R., Alterman, A.I., Heyashida, M., O'Brien, C.P. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992, 49: 876-88.
22. O'Malley, S.S., Jafee, A.J., Chang, G. et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992, 49: 876-80.
23. Croop, R.S., Faulkner, E.B., Labriola, D.F. et al. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. Arch Gen Psychiatry 1997, 54: 1130-5.
24. Volpicelli, J.R., Watson, N.T., King, A.C. et al. Effect of naltrexone "high" in alcoholics. Am J Psychiatry 1995, 152: 613-5.
25. Swift, R.M., Whelihan, W., Kuznetsov, O. et al. Naltrexone induced alterations in human ethanol intoxication. Am J Psychiatry 1994, 451: 1463-7.
26. King, A.C., Volpicelli, J.R., Frazer, A. et al. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 1997, 129: 15-22.
27. Mason, B.J. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Ther 1996, 20 (Suppl.): 10-6.
28. Spotlight on treatment of substance abuse disorders. Prous Science Daily Essentials Sept 4, 1998.
29. Ban receives FDA approval for generic form of ReVia. Prous Science Daily Essentials May 18, 1998.
30. Naranjo, C.A., Sellers, E.M., Roech, C.A. et al. Zimeldine-induced variations in alcohol intake by non-depressed heavy drinkers. Clin Pharmacol Ther 1984, 35: 374-81.
31. Naranjo, C.A., Sellers, E.O., Sullivan, J.T. et al. The serotonin uptake inhibitor citalopram, attenuates ethanol intake. Clin Pharmacol Ther 1987, 41: 266-74.
32. Naranjo, C.A., Bremner, K.E. Serotonin uptake inhibitors decrease desirability, liking and consumption of alcohol. Proc Am Coll Neuropsychopharmacol (Dec, San Juan) 1991, 84.
33. Pettinati, H.M. Use of serotonin selective phar-macotherapy in the treatment of alcohol dependence. Alcohol Clin Exp Res 1996, 20: 23-9.
34. Sellers, E.M., Higgins, G.A., Tomkins, D.M. Serotonin receptor subtypes and alcohol consumption. Proc Am Coll Neuropsychopharmacol (Dec, San Juan) 1991, 84.
35. 3 receptor antagonist reduces voluntary ethanol consumption in rats. Pharmacol Biochem Behav 1992, 41: 847-50.
36. Hodge, C.W., Samson, B.H., Lewis, R.S., Erickson, H.L. Specific decreases in ethanol but not water-reinforced responding produced by the 5-HT antagonist ICS 201-930. Alcohol 1993, 10: 191-6.
37. Johnson, B.A., Jasinski, D.R., Gelloway, G.P. et al. Ritanserin in the treatment of alcohol dependence - A multicenter clinical trial. Psychopharmacology 1996, 128: 206-15.
38. Daoust, M., Legrand, E., Tran, G. et al. Acamprosate treatment differentially modulates synaptosomal GABA uptake in chronically alcoholised rats. Alcohol Clin Exp Res 1990, 14: 281.
39. Daoust, M., Legrand, E., Gewiss, M. et al. Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 1992, 41: 669-74.
40. Bouchenafa, O., Cwynarski, K., Kittleton, J. Interactions between excitatory amino acids and acamprosate in a cell culture model of ethanol dependence. Alcohol Clin Exp Res 1990, 351: 237-42.
41. Zeise, M.L., Kasparov, S., Capogna, M. et al. Calcium diacetylhomotaurinate (Ca-AOTA) decreases the action of excitatory amino acids in the rat neocortex in vitro. Eur J Pharmacol 1993, 231: 47-52.
42. Whitworth, A.B., Fischer, F., Lesch, O.M. et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996, 34: 1438-42.
43. Poldrugo, F. Acamprosate treatment in long-term community-based alcohol rehabilitation programme. Addiction 1997, 92: 1537-46.
44. Dorus, W., Ostrow, D., Anton, R. et al. Lithium treatment of depressed and non-depressed alcoholics. JAMA 1989, 262: 1646-52.
45. Ritson, B. Pharmacotherapy in alcohol problems. Curr Opin Psychiatry 1998, 11: 285-8.
46. Agasti, V. The efficacy of controlled trials of alcohol misuse treatments in maintaining abstinence: A meta-analysis. Int J Addict 1194, 29: 759-69.
47. Agasti, V. The efficacy of treatments in reducing alcohol consumption: A meta-analysis. Int J Addict 1995, 30: 1067-77.